一项长期扩展研究,旨在评估 BIIB059(利替非利单抗)在患有活动性亚急性皮肤红斑狼疮 (CLE) 和/或伴有或不伴有全身表现且抗疟治疗难治性和/或不耐受的慢性 CLE 成人患者中的持续安全性和有效性 (AMETHYST LTE)
一项多中心、开放标签、单臂、第 3 期、长期扩展研究,旨在评估 BIIB059(Litifilimab)在患有活动性亚急性皮肤红斑狼疮和/或伴或不伴全身性慢性皮肤红斑狼疮的成年参与者中的持续安全性和有效性表现和抗疟治疗难治性和/或不耐受
该研究的主要目的是评估完成母研究 230LE301 (NCT05531565) 的受试者的长期安全性和耐受性 BIIB059 (litifilimab),患有活动性亚急性 CLE 和/或慢性 CLE,伴或不伴全身表现以及难治性和/或不耐受抗疟治疗。
该研究的次要目标是评估litifilimab对疾病活动性的长期影响以及litifilimab在患有活动性亚急性CLE和/或慢性CLE(伴或不伴全身表现以及难治性和/或不耐受)的参与者中预防疾病损害的效果抗疟药;评估 Litifilimab 对预防患有系统性红斑狼疮 (SLE) 的 CLE 参与者狼疮发作的长期效果;评估接受litifilimab治疗的参与者长期使用口服皮质类固醇(OCS);评估 litifilimab 对参与者报告的健康相关生活质量 (HRQoL) 的影响;评估litifilimab对实验室参数的长期影响;评估litifilimab的免疫原性和药代动力学(PK)。
研究概览
详细说明
该研究的主要目的是评估完成母研究 230LE301 (NCT05531565) 的受试者的长期安全性和耐受性 BIIB059 (litifilimab),患有活动性亚急性 CLE 和/或慢性 CLE,伴或不伴全身表现以及难治性和/或不耐受抗疟治疗。
该研究的次要目标是评估litifilimab对疾病活动性的长期影响以及litifilimab在患有活动性亚急性CLE和/或慢性CLE(伴或不伴全身表现以及难治性和/或不耐受)的参与者中预防疾病损害的效果抗疟药;评估 litifilimab 对预防患有 SLE 的 CLE 参与者的狼疮发作的长期效果;评估接受litifilimab治疗的参与者长期使用口服皮质类固醇(OCS);评估 litifilimab 对参与者报告的健康相关生活质量 (HRQoL) 的影响;评估litifilimab对实验室参数的长期影响;评估litifilimab的免疫原性和药代动力学(PK)。
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100730
- Beijing Tongren Hospital, Capital Medical University
-
-
Guangdong
-
Shenzhen、Guangdong、中国、518029
- Shenzhen Second People's Hospital
-
-
Guangdongsheng
-
Dongguan、Guangdongsheng、中国、523059
- Dongguan People's Hospital
-
Guangzhou、Guangdongsheng、中国、510515
- Nanfang Hospital of Southern Medical University
-
-
Húnánsheng
-
Changsha、Húnánsheng、中国、410011
- The Second Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210042
- Hospital for Skin Diseases, Chinese Academy of Medical Sciences
-
-
Shànghaishì
-
Shanghai、Shànghaishì、中国、200443
- Shanghai Skin Disease Hospital
-
-
Yun'Nan
-
Kunming、Yun'Nan、中国、650101
- The Second Affiliated Hospital of Kunming Medical University
-
-
-
-
-
Sofia、保加利亚、1431
- DCC 'Alexandrovska', EOOD
-
Sofia、保加利亚、1463
- DCC Focus 5 - MEOH OOD
-
-
Sofia City Province
-
Sofia、Sofia City Province、保加利亚、1612
- University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD
-
-
-
-
Alberta
-
Calgary、Alberta、加拿大、T2W 4X9
- Laser Rejuvenation Clinics, Inc.
-
-
Quebec
-
Sherbrooke、Quebec、加拿大、J1L 0H8
- DIEX Recherche Sherbrooke Inc.
-
-
-
-
-
Pécs、匈牙利、07632
- Pécsi Tudományegyetem Klinikai Központ
-
-
-
-
-
Taichung、台湾、407219
- Taichung Veterans General Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
-
-
-
-
Barranquilla、哥伦比亚、80020
- Centro de Investigacion Medico Asistencial S.A.S
-
-
Cundinamarca
-
Zipaquirá、Cundinamarca、哥伦比亚、250252
- Healthy Medical Center
-
-
-
-
-
Belgrade、塞尔维亚、11000
- University Clinical Center of Serbia
-
Belgrade、塞尔维亚、11000
- Institute of Rheumatology_Belgrade
-
-
-
-
-
Chihuahua City、墨西哥、31000
- Investigacion y Biomedicina de Chihuahua, S.C.
-
Guadalajara、墨西哥、44950
- Centro de investigacion medica y reumatologia
-
-
Mexico City
-
Mexico City、Mexico City、墨西哥、06700
- Clinstile, S.A. de C.V.
-
-
-
-
-
Rio de Janeiro、巴西、22470-220
- IDERJ - Instituto de Dermatologia e Estética do Brasil Ltda
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、巴西、40150-150
- Clínica SER da Bahia
-
-
Federal District
-
Brasília、Federal District、巴西、70200-730
- L2IP - Instituto de Pesquisas Clínicas Ltda.
-
-
Mato Grosso
-
Santo Ângelo、Mato Grosso、巴西、78020-500
- IPC MT Instituto de Pesquisas Clinicas do Mato Grosso
-
-
Minas Gerais
-
Juiz de Fora、Minas Gerais、巴西、36010-570
- CMiP - Centro Mineiro de Pesquisa
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90035-903
- Hospital de Clinicas de Porto Alegre
-
Porto Alegre、Rio Grande do Sul、巴西、90430-001
- Nucleo de Pesquisa Clinica do Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90480-000
- LMK Serviços Médicos S/S Ltda
-
-
São Paulo
-
São Paulo、São Paulo、巴西、04266-010
- CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos
-
-
-
-
-
Berlin、德国、10117
- Charité - Campus Charité Mitte
-
-
Bavaria
-
Erlangen、Bavaria、德国、91054
- Universitaetsklinikum Erlangen
-
-
Lower Saxony
-
Bad Bentheim、Lower Saxony、德国、48455
- Fachklinik Bad Bentheim Dermatologie
-
Oldenburg、Lower Saxony、德国、26133
- Klinikum Oldenburg AoeR
-
-
North Rhine-Westphalia
-
Münster、North Rhine-Westphalia、德国、48149
- Universitaetsklinikum Muenster
-
-
Saxony
-
Dresden、Saxony、德国、01307
- Universitaetsklinikum Carl Gustav Carus TU
-
-
Saxony-Anhalt
-
Halle、Saxony-Anhalt、德国、06120
- Universitaetsklinikum Halle (Saale)
-
-
-
-
-
Florence、意大利、50121
- Università degli studi di Firenze
-
Milan、意大利、20122
- Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
-
-
-
-
-
Košice、斯洛伐克、04011
- Artromac n.o.
-
-
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、457-8510
- JCHO Chukyo Hospital
-
Nagoya、Aichi-ken、日本、460-0001
- NHO Nagoya Medical Center
-
-
Fukui
-
Yoshida-gun、Fukui、日本、910-1193
- University of Fukui Hospital
-
-
Fukuoka
-
Kitakyushu-shi、Fukuoka、日本、807-8556
- Hospital of the University of Occupational and Environmental Health
-
-
Hyōgo
-
Kakogawa-shi、Hyōgo、日本、675-8611
- Kakogawa Central City Hospital
-
-
Ishikawa-ken
-
Kanazawa、Ishikawa-ken、日本、920-8641
- Kanazawa University Hospital
-
-
Kanagawa
-
Kawasaki-shi、Kanagawa、日本、216-8511
- St. Marianna University Hospital
-
Yokohama、Kanagawa、日本、236-0004
- Yokohama City University Hospital
-
-
Kumamoto
-
Kumamoto、Kumamoto、日本、860-8556
- Kumamoto University Hospital
-
-
Miyagi
-
Sendai、Miyagi、日本、980-8574
- Tohoku University Hospital
-
-
Nagasaki
-
Nagasaki、Nagasaki、日本、852-8501
- Nagasaki University Hospital
-
-
Niigata
-
Niigata、Niigata、日本、951-8520
- Niigata University Medical & Dental Hospital
-
-
Osaka
-
Osaka、Osaka、日本、543-8922
- Osaka Keisatsu Hospital
-
-
Tokyo-To
-
Itabashi-ku、Tokyo-To、日本、173-8606
- Teikyo University Hospital
-
-
-
-
-
Las Condes、智利、7580206
- Centro Medico SkinMed
-
Santiago、智利、8420383
- CIEC - Centro Internacional de Estudios Clínicos
-
Valdivia、智利、5090000
- Clinical Research Chile SpA
-
-
-
-
-
Paris、法国、75020
- Hôpital Tenon
-
-
Calvados
-
Caen、Calvados、法国、14033
- CHU de Caen - Hopital de la Cote de Nacre
-
-
Haute Garonne
-
Toulouse、Haute Garonne、法国、31059
- Hopital Larrey
-
-
Herault
-
Montpellier、Herault、法国、34295
- Hopital Saint Eloi
-
-
Rhone
-
Lyon、Rhone、法国、69003
- Hopital Edouard Herriot - CHU Lyon
-
-
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、波兰、02-962
- Royalderm_Warszawa
-
-
Podkarpackie Voivodeship
-
Rzeszów、Podkarpackie Voivodeship、波兰、35-055
- Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie
-
-
-
-
-
Solna、瑞典、17000
- Karolinska Universitetssjukhuset - Solna
-
-
-
-
-
Sankt Gallen、瑞士、9007
- Kantonsspital St. Gallen
-
-
Lucerne (Luzern)
-
Lausanne、Lucerne (Luzern)、瑞士、CH-1011
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35233
- University of Alabama at Birmingham - (UAB)
-
-
Arizona
-
Phoenix、Arizona、美国、85032
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Los Angeles、California、美国、90045
- Dermatology Research Associates
-
Upland、California、美国、91786
- Inland Rheumatology Clinical Trials, Inc.
-
-
Michigan
-
Ann Arbor、Michigan、美国、48103
- David Fivenson, MD, Dermatology, PLLC
-
Troy、Michigan、美国、48084
- Revival Research Institute, LLC
-
-
Missouri
-
St Louis、Missouri、美国、63110
- Saint Louis University
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599-7280
- Thurston Arthritis Research Center
-
Durham、North Carolina、美国、27710
- Duke Dermatology South Durham
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- University of Cincinnati Health Physicians Office Dermatology
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- University of Pennsylvania
-
-
Texas
-
Dallas、Texas、美国、75390-8896
- UT Southwestern Medical Center
-
Grapevine、Texas、美国、76034
- Precision Comprehensive Clinical Research Solutions
-
-
-
-
Greater London
-
London、Greater London、英国、E11 1NR
- Whipps Cross University Hospital
-
-
West Midlands
-
Birmingham、West Midlands、英国、B15 2GW
- Queen Elizabeth Hospital
-
-
West Yorkshire
-
Chapel Allerton、West Yorkshire、英国、LS7 4SA
- Chapel Allerton Hospital
-
-
-
-
-
Manila、菲律宾、1000
- University of the Philippines Manila - Philippine General Hospital
-
Manila、菲律宾、1012
- Jose R. Reyes Memorial Medical Center
-
-
Batangas
-
Lipa City、Batangas、菲律宾、4127
- Mary Mediatrix Medical Center
-
-
La Union
-
San Fernando City, La Union、La Union、菲律宾、2500
- Lorma Medical Center
-
-
National Capital Region (ncr)
-
Quezon City、National Capital Region (ncr)、菲律宾、1102
- St. Luke's Medical Center
-
-
-
-
Coimbra District
-
Coimbra、Coimbra District、葡萄牙、3000-075
- Centro Hospitalar e Universitário de Coimbra, E.P.E (HUC)
-
-
-
-
-
Barcelona、西班牙、8041
- Hospital de La Santa Creu i Sant Pau
-
Barcelona、西班牙、8003
- Hospital Del Mar
-
Seville、西班牙、41013
- Hospital Universitario Virgen del Rocío
-
-
Cantabria
-
Valladolid、Cantabria、西班牙、47012
- Hospital Universitario Río Hortega
-
-
Córdoba
-
Córdoba、Córdoba、西班牙、14004
- Hospital Universitario Reina Sofia
-
-
Madrid
-
Majadahonda、Madrid、西班牙、28222
- Hospital Universitario Puerta de Hierro Majadahonda
-
-
-
-
-
Buenos Aires、阿根廷、C1406AGA
- APRILLUS Asistencia e Investigacion
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、阿根廷、S2000PBJ
- Instituto CAICI
-
-
Tucumán Province
-
San Miguel de Tucumán、Tucumán Province、阿根廷、T4000AXL
- Centro de Investigaciones Médicas Tucuman
-
San Miguel de Tucumán、Tucumán Province、阿根廷、4000
- Investigaciones Clinicas Tucuman
-
-
-
-
-
Seoul、韩国、03722
- Severance Hospital, Yonsei University Health System
-
Seoul、韩国、06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul、韩国、04763
- Hanyang University Seoul Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
主要纳入标准:
- 完成研究治疗家长研究(230LE301 [NCT05531565],A 部分或 B 部分)的参与者(在第 48 周接受治疗并在第 52 周参加最后一次研究评估访视)。
- 参与者有能力了解研究的目的和风险,提供知情同意,并根据国家和当地隐私法规授权使用机密健康信息。
主要排除标准:
- 早期 A 部分或 B 部分家长研究 (230LE301 [NCT05531565]) 治疗终止者(在第 48 周之前停止研究治疗的参与者)。
- 早期 A 部分或 B 部分家长研究终止者[在第 52 周之前退出家长研究且未完成家长研究延长治疗期 (ETP) 的参与者]。
- 患有任何其他医学疾病、病症或异常,导致研究者认为不适合参加长期扩展 (LTE) 研究的参与者。
注:其他协议定义的包含/排除标准可能适用。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:BIIB059
Participants will receive BIIB059 (litifilimab) subcutaneously (SC), once every 4 weeks up to Week 204 in the LTE period.
|
按照治疗组的规定给药。
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Percentage of Participants who Achieve a Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity Score (CLASI)-70 Response, Defined as a 70% Decrease in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
|
Percentage of Participants who Achieve a CLASI-50 Response, Defined as a 50% Decrease in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
|
Percentage of Participants who Achieve a CLASI-90 Response, Defined as a 90% Decrease in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
|
Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
|
Percentage of Participants who Achieve a CLA-IGA-R Other Morphologic Characteristics (OMC) Score of 0
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
|
Percentage of Participants With a CLASI-50 Response Among CLASI-50 Responders at LTE Baseline
大体时间:Day 1 (LTE Baseline) up to 232 weeks
|
Day 1 (LTE Baseline) up to 232 weeks
|
|
Percentage of Participants With a CLASI-90 Response Among CLASI-90 Responders at LTE Baseline
大体时间:Day 1 (LTE Baseline) up to 232 weeks
|
Day 1 (LTE Baseline) up to 232 weeks
|
|
Percentage of Participants With a CLA-IGA-R Erythema Score of 0 or 1 Among Participants With a CLA-IGA-R Erythema Score of 0 or 1 at LTE Baseline
大体时间:Day 1 (LTE Baseline) up to 232 weeks
|
Day 1 (LTE Baseline) up to 232 weeks
|
|
Percentage of Participants With CLA-IGA-R OMC Score of 0 or 1 and at Least 1 Level of Improvement From Baseline Value(Parent Study) Among Participants With CLA IGA R OMC Score of 0 or 1 and at Least 1 Level Improvement From Baseline Value(Parent Study)
大体时间:Day 1 (LTE Baseline) up to 232 weeks
|
Day 1 (LTE Baseline) up to 232 weeks
|
|
Percentage of Participants With a CLASI-70 Response Among CLASI-50 Responders at LTE Baseline
大体时间:Day 1 (LTE Baseline) up to 232 weeks
|
Day 1 (LTE Baseline) up to 232 weeks
|
|
Percentage of Participants With Loss of Response, Defined as an Increase of ≥ 7 Points in CLASI-A Total Score From Baseline
大体时间:Day 1 (LTE Baseline) up to 232 weeks
|
Day 1 (LTE Baseline) up to 232 weeks
|
|
Percentage of Participants who Achieve a CLASI A Score of 0 to 3
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
|
Percentage of Participants who Achieve a CLASI-A Score of 0 to 5
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
|
Percentage of Participants With a CLASI-A 0 to 3 Response Among CLASI-A 0 to 3 Responders at LTE Baseline
大体时间:Day 1 (LTE Baseline) up to 232 weeks
|
Day 1 (LTE Baseline) up to 232 weeks
|
|
Absolute Change From Baseline in CLASI-A Score of Parent Study (NCT05531565) to Week 208
大体时间:Day 1 (Baseline of Parent study) up to 208 weeks
|
Day 1 (Baseline of Parent study) up to 208 weeks
|
|
Percent Change From Baseline in CLASI-A Score of Parent Study (NCT05531565) to Week 208
大体时间:Day 1 (Baseline of Parent study) up to 208 weeks
|
Day 1 (Baseline of Parent study) up to 208 weeks
|
|
Absolute Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index Damage (CLASI-D) Score From Baseline Value (Parent Study [NCT05531565]) to Week 208
大体时间:Up to 208 weeks
|
Up to 208 weeks
|
|
Percent Change in CLASI-D Score From Baseline Value (Parent Study [NCT05531565]) to Week 208
大体时间:Up to 208 weeks
|
Up to 208 weeks
|
|
Annualized Mild/Moderate and Severe Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index Flare Index (SFI) Rates
大体时间:Up to 208 weeks
|
Up to 208 weeks
|
|
Percentage of Participants With Oral Corticosteroid (OCS) Dose Among Participants who Used OCS at Baseline in the Parent Study (NCT05531565)
大体时间:Day 1 (Baseline of Parent study) up to 208 weeks
|
Day 1 (Baseline of Parent study) up to 208 weeks
|
|
Percentage of Participants With OCS ≤ 7.5 Milligrams per day (mg/day) Among Participants who Used OCS at Baseline in the Parent Study (NCT05531565)
大体时间:Day 1 (Baseline of Parent study) up to 208 weeks
|
Day 1 (Baseline of Parent study) up to 208 weeks
|
|
Percentage of Participants With OCS ≤ 5.0 mg/day Among Participants who Used OCS at Baseline in the Parent Study (NCT05531565)
大体时间:Day 1 (Baseline of Parent study) up to 208 weeks
|
Day 1 (Baseline of Parent study) up to 208 weeks
|
|
Change From Baseline Value (Parent Study [NCT05531565]) in Cutaneous Lupus Erythematosus - Quality of Life (CLE-QoL) at Week 208
大体时间:Baseline, Week 208
|
Baseline, Week 208
|
|
Change From Baseline Value (Parent Study [NCT05531565]) in European Quality of Life - 5-Dimensions Questionnaire, 3-Level Version (EQ-5D-3L) at Week 104
大体时间:Baseline, Week 104
|
Baseline, Week 104
|
|
Change From Baseline Value (Parent Study [NCT05531565]) in 36-Item Short Form Survey (SF-36) (acute version) at Week 104
大体时间:Baseline, Week 104
|
Baseline, Week 104
|
|
Change From Baseline Value (Parent Study [NCT05531565]) in Work Productivity and Activity Impairment (WPAI): Lupus at Week 104
大体时间:Baseline, Week 104
|
Baseline, Week 104
|
|
Change From Baseline Value (Parent Study [NCT05531565]) in Patient Health Questionnaire-9 (PHQ-9) at Week 104
大体时间:Baseline, Week 104
|
Baseline, Week 104
|
|
Change From Baseline Value (Parent Study [NCT05531565]) in Subject Global Assessment of Skin - Follow-up (SGA-Skin-FU) at Week 208
大体时间:Baseline, Week 208
|
Baseline, Week 208
|
|
Change From Baseline Value (Parent Study [NCT05531565]) in Numerical Rating Scale (NRS) for Pain in Skin Rash at Week 208
大体时间:Baseline, Week 208
|
Baseline, Week 208
|
|
Change From Baseline Value (Parent Study [NCT05531565]) in Numerical Rating Scale (NRS) for Itch in Skin Rash at Week 208
大体时间:Baseline, Week 208
|
Baseline, Week 208
|
|
Number of Participants With Clinically Relevant Change From Baseline Value (Parent Study [NCT05531565]) in Standard Laboratory Parameters
大体时间:Up to 208 weeks
|
Up to 208 weeks
|
|
Number of Participants With Clinically Relevant Change From Baseline Value (Parent Study [NCT05531565]) in Electrocardiogram (ECG) Results
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
|
Number of Participants With Anti-BIIB059 Antibodies in Serum
大体时间:Up to 232 weeks
|
Up to 232 weeks
|
|
Serum Concentration of Litifilimab
大体时间:Pre-dose up to 232 weeks
|
Pre-dose up to 232 weeks
|
|
Percentage of Participants With a CLASI-70 Response Among CLASI-70 Responders at Long-Term Extension (LTE) Baseline
大体时间:Day 1 (LTE Baseline) up to 232 weeks
|
Day 1 (LTE Baseline) up to 232 weeks
|
合作者和调查者
赞助
调查人员
- 研究主任:Medical Director、Biogen
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.